A bone lesion on MRI is any area within a bone that looks different from the surrounding normal bone marrow. It can be as harmless as a small cluster of fat cells or fibrous tissue, or it can signal something that needs further evaluation. The vast majority of bone lesions found on MRI are benign, and incidental bone lesions show up in roughly 2% to 20% of people getting scans for completely unrelated reasons.
If your MRI report mentions a bone lesion, understanding what radiologists look for and how they classify these findings can help you make sense of your results.
How MRI Detects Bone Lesions
MRI works by detecting how water and fat molecules in your body respond to magnetic fields. Different tissues light up or darken depending on the type of MRI sequence used. Two main sequences matter for bone lesions: T1-weighted images and T2-weighted images.
Normal bone marrow in adults contains a lot of fat, which appears bright on T1 images. When something replaces that fatty marrow, whether it’s fluid, inflammation, or abnormal cells, the area turns dark on T1 images. On T2 images, water-rich areas light up bright. So a lesion filled with fluid or swelling will glow on T2, while dense, hardened (sclerotic) bone stays dark on both.
This combination of signals gives radiologists a fingerprint for each type of lesion. A simple bone cyst, for example, looks very different from a metastatic deposit because the water content, fat content, and internal structure each produce distinct signal patterns. Radiologists also use fat-suppression sequences (often called STIR), which silence the fat signal so that areas of swelling or abnormal tissue stand out more clearly.
Benign Lesions: The Most Common Findings
Most bone lesions discovered on MRI fall into a category radiologists informally call “don’t touch” lesions, meaning they’re so clearly benign that no further workup is needed. The most common include:
- Enchondromas: Small islands of cartilage, usually found in the hands or near the ends of long bones. On MRI they appear bright on T2 images because cartilage holds a lot of water, with thin dark lines running through them in a lobular pattern. They sit in the center of the bone and rarely cause symptoms.
- Non-ossifying fibromas: Pockets of fibrous tissue found near the growth plates of the thighbone or shinbone, especially in children and young adults. They have a characteristic scalloped, sclerotic border and typically shrink or harden completely as a person finishes growing.
- Bone islands: Dense spots of compact bone within the spongy interior. They stay dark on both T1 and T2 images because they contain no water or fat to generate signal.
- Simple bone cysts: Fluid-filled cavities that light up intensely on T2 and STIR sequences, looking very similar to water.
These lesions can look alarming on a report, but their imaging patterns are well-established enough that experienced radiologists can identify them without a biopsy.
Bone Marrow Edema vs. a True Lesion
One of the most common findings that gets labeled a “bone lesion” is actually bone marrow edema, which is swelling inside the bone rather than a distinct mass. It shows up as a hazy bright area on T2 and STIR images with only mild darkening on T1. This pattern is different from a solid lesion, which tends to replace the marrow completely and create a more dramatic dark signal on T1.
Bone marrow edema typically results from stress reactions (like overuse injuries in runners), arthritis, small fractures, or inflammation. It usually resolves on its own or with treatment of the underlying cause. Standard X-rays often look completely normal even when edema is clearly visible on MRI, which is why MRI catches these problems earlier. Edema generally lacks a distinct border, doesn’t form a mass, and doesn’t extend into the soft tissues around the bone.
Warning Signs of a Malignant Lesion
Radiologists look for several red flags that raise concern about a cancerous bone lesion. The key features include a large soft tissue mass extending beyond the bone, destruction of the outer bone shell (cortex), aggressive-looking periosteal reaction (the bone’s outer lining lifting or becoming irregular), and mixed or patchy signal on T2 images rather than a uniform appearance. Larger lesions located deep within the body are more concerning than small, well-defined ones near the surface.
On T1 images, metastatic cancer deposits replace the normal bright fatty marrow with dark signal. On T2 and STIR sequences, most malignant lesions appear bright because of their high water content, though some bone-forming metastases (called blastic metastases, common in prostate cancer) can appear dark on T2 as well because of their dense, sclerotic makeup.
The World Health Organization classifies bone tumors on a spectrum: benign, intermediate (locally aggressive but unlikely to spread), intermediate (with rare potential to spread), and malignant. In practice, the intermediate categories are often grouped with benign tumors because they behave similarly. True malignant bone tumors are relatively uncommon compared to benign findings.
When Contrast Dye Is Used
You might wonder whether your scan needed contrast (gadolinium) injected into a vein. For most bone lesions, contrast adds little diagnostic information. MRI is primarily used to determine how far a lesion extends within the bone and into surrounding structures, and the standard non-contrast sequences handle that well.
Contrast becomes useful in specific situations: evaluating whether a tumor is responding to chemotherapy by measuring how much tissue has died, determining whether a tumor near a joint invades the joint itself, or making a small lesion called an osteoid osteoma easier to see. For a first-time incidental bone lesion, contrast is generally not required.
How Radiologists Score Your Lesion
The American College of Radiology developed a scoring system called Bone-RADS to standardize how incidental bone lesions are managed. It works similarly to the scoring systems used for breast or lung findings, giving each lesion a number that guides what happens next.
- Score 0: The lesion can’t be fully characterized from the current images. More imaging is needed.
- Score 1: Very low risk. This is a classic benign lesion like a non-ossifying fibroma. No further workup is needed unless symptoms develop.
- Score 2: Low risk. The lesion looks benign but may benefit from a short follow-up scan in 3 to 6 months to confirm it stays stable, or a different imaging test (like CT) to better see internal details.
- Score 3: Intermediate risk. The lesion has some features that aren’t clearly benign, especially in someone with a history of cancer. A biopsy is likely recommended.
- Score 4: High risk. The lesion has features like a soft tissue mass, cortical destruction, or internal enhancement that make it suspicious for malignancy. Biopsy and referral to an orthopedic oncologist are recommended.
Not every radiology report uses this exact scoring system, but the logic behind it shapes how most radiologists communicate their findings and recommendations.
What Typically Happens After the Scan
If your lesion has the classic appearance of a known benign entity, your radiologist will likely describe it by name and note that no further imaging is needed. This is the most common outcome.
For lesions that are dark on T1 and bright on T2 but don’t match a specific benign pattern, the next step is often a CT scan. CT excels at showing the internal structure of bone, including calcifications and matrix patterns that MRI can miss. This additional detail is frequently enough to make a confident diagnosis without a biopsy.
If the lesion remains indeterminate after additional imaging, follow-up MRI at 6 months is standard practice, followed by another at 6 months and then at 12 months. A lesion that stays the same size over this period is almost certainly benign. One that grows, changes character, or develops new features like cortical destruction will be escalated to biopsy and specialist referral.
For patients with a known cancer elsewhere in the body, even a small or innocent-looking bone lesion gets more scrutiny because bones are a common destination for metastatic spread. In those cases, a bone scan or PET scan may be ordered to check whether the lesion is metabolically active and whether similar lesions exist elsewhere in the skeleton.